Fig. 2From: Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinomaKaplan‒Meier estimates of overall survival (A), progression-free survival (B), clinical benefit histogram (C) of 139 advanced cholangiocarcinoma patients receiving PD-1 inhibitor-based therapy stratified by MSI status. MSI-H, microsatellite instability-high; MSS, microsatellite stabilityBack to article page